NYSE:OGEN
ORAGENICS INC
Oragenics Inc. is a biopharmaceutical developer focused on creating new treatments for autoimmune diseases using an innovative proprietary platform technology.
Key Metrics
Investment Thesis
Bull Case
Investors may view OGEN as a high-potential turnaround story if its proprietary platform successfully advances key clinical candidates to late-stage trials or approval. The recent $6.0M in financing cash flow suggests active investor interest and potential support for the company's development efforts. If the company can demonstrate clear progress in its pipeline, current valuations could reflect significant upside upon successful milestones.
Bear Case
The stock carries extreme risk due to a massive retained earnings deficit of $216.8M and zero revenue, indicating the business model has not yet proven commercially viable. With total liabilities exceeding total assets and negative operating cash flow, the company is in a precarious financial position that could lead to insolvency without immediate funding. Investors should avoid this stock unless they have a high risk tolerance for biotech failures and dilution events.
About ORAGENICS INC
Oragenics Inc. (NYSE: OGEN) is a biopharmaceutical company focused on developing novel therapeutic candidates, primarily leveraging its proprietary platform to create treatments for autoimmune diseases and other inflammatory conditions. The company operates in the competitive drug discovery and development sector, utilizing significant research and development expenditures to advance its pipeline of potential medicines.
Analysis
Management Discussion
The company reported a net loss of $10.6M in 2024, with operating expenses totaling $10.6M driven largely by research and development costs of $4.1M and general administrative expenses of $6.4M. Despite having cash reserves of approximately $865K and recent financing inflows of $6.0M, the net change in cash was negative $2.6M, highlighting the intense capital requirements typical of the biotech sector.
Industry Overview
The biopharmaceutical industry is characterized by long development cycles, high failure rates, and significant capital requirements before products reach the market. Companies in this space often operate at a loss for years while investing heavily in research to bring novel treatments to patients with unmet medical needs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $131.5K | $37.7K | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $131.5K | $37.7K | $0 |
| Operating Expenses | $14.5M | $20.9M | $10.6M |
| Operating Income | $-14.4M | $-20.9M | $-10.6M |
| R&D | $10.1M | $15.5M | $4.1M |
| G&A | $4.5M | $5.5M | $6.4M |
| Stock-Based Comp | $742.2K | $1.0M | $516.0K |
| D&A | $44.7K | $27.4K | — |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $127.2K | $249.2K | $-9.1K |
| Interest Expense | $15.1K | $30.6K | — |
| Interest Income | $135.9K | $210.4K | $45.9K |
| Pre-Tax Income | $-14.3M | $-20.7M | $-10.6M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-14.3M | $-20.7M | $-10.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-14.3M | $-20.7M | $-10.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-14.3M | $-20.7M | $-10.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $14.3M | $3.9M | $1.5M |
| Cash & Equivalents | $11.4M | $3.5M | $864.8K |
| Prepaid Expenses | $2.9M | $382.3K | $607.7K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $468.5K | $1.1M | $0 |
| PP&E (Net) | $121.1K | $0 | — |
| Operating Leases | $347.4K | $9.8K | — |
| Other LT Assets | $0 | $1.1M | — |
| Total Assets | $14.8M | $5.0M | $1.5M |
| Current Liabilities | $1.6M | $1.8M | — |
| Current Leases | $204.4K | $9.8K | — |
| Other Current Liab | $579.0K | $1.6M | — |
| Long-Term Liabilities | $152.4K | $0 | — |
| LT Operating Leases | $152.4K | — | — |
| Other LT Liab | $0 | — | — |
| Total Liabilities | $1.7M | $1.8M | $1.7M |
| Shareholders' Equity | $13.0M | $3.2M | $-211.9K |
| Paid-In Capital | $197.0M | $207.8M | $216.6M |
| Retained Earnings | $-185.6M | $-206.2M | $-216.8M |
| Total L&E | $14.8M | $5.0M | $1.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-14.3M | $-20.7M | $-10.6M |
| Non-Cash Adjustments | $-3.0M | $15.7M | $2.6M |
| Working Capital Changes | $2.1M | $-2.3M | $-613.1K |
| Cash from Operations | $-15.2M | $-7.3M | $-8.6M |
| Capital Expenditures | $127.5K | — | — |
| Cash from Investing | $-115.5K | $-936.3K | $0 |
| Cash from Financing | $-494.9K | $283.9K | $6.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-15.8M | $-7.9M | $-2.6M |
| Beginning Cash | $27.3M | $11.4M | $3.5M |
| Ending Cash | $11.4M | $3.5M | $864.8K |
Frequently Asked Questions
How does ORAGENICS INC make money?
The company's operations are primarily centered on drug discovery and development, with revenue streams currently being minimal as it focuses on advancing its clinical pipeline through research and development spending rather than commercial product sales.
What are the main risks for OGEN?
The company faces substantial risk from its significant accumulated deficit and negative operating cash flow, which could lead to liquidity constraints without future capital raises. As a pre-revenue biotech firm, OGEN is entirely dependent on successful clinical trial outcomes and regulatory approval to generate future revenue. The high burn rate indicates potential dilution for shareholders through frequent equity offerings if the company cannot secure sufficient funding.
What is OGEN's competitive advantage?
Oragenics possesses a proprietary platform technology that enables the creation of novel therapeutic candidates, offering potential differentiation in the crowded autoimmune disease market. The company maintains a highly specialized scientific team dedicated to translating early-stage discoveries into viable drug candidates.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.